Proportion of patients achieving a response as measured by modified SLE Responder Index (SRI) with no BILAG A or no more than 1 BILAG B organ domain flares at 52 weeks [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

Have received intravenous immunoglobulin (IVIg) within 180 days of randomization

Have active or recent infection within 30 days of screening

Have had a serious infection within 90 days of randomization

Have evidence or test positive for Hepatitis B

Have Hepatitis C

Are human immunodeficiency virus (HIV) positive

Have evidence of active or latent tuberculosis (TB)

Presence of significant laboratory abnormalities at screening

Have had a malignancy in the past 5 years, except for cervical carcinoma in-situ or basal cell or squamous epithelial skin cell that were completely resected with no reoccurrence in the 3 yrs prior to randomization

Have received greater than 40 mgs of prednisone or equivalent in the past 30 days

Have changed your dose of antimalarial drug in the past 30 days

Have changed your dose of immunosuppressive drug in the past 90 days

Have previously received rituximab

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01205438

United States: Food and Drug AdministrationAustralia: Department of Health and Ageing Therapeutic Goods AdministrationBrazil: Ministry of HealthCanada: Health CanadaEcuador: Public Health MinistryFrance: Ministry of HealthHungary: National Institute of PharmacyIndia: Ministry of HealthIsrael: Ministry of HealthLatvia: Institutional Review BoardMalaysia: Ministry of HealthMexico: Ministry of HealthMorocco: Ministry of Public HealthNew Zealand: Ministry of HealthRomania: National Medicines AgencyRussia: Ministry of Health of the Russian FederationSerbia: Ethics CommitteeSouth Africa: Department of HealthSpain: Ministry of HealthTaiwan: Department of HealthTunisia: Ministry of Public Health